Risk of Dislodgement of Ultrathin Drug Eluting Stents Versus Thick Drug Eluting Stents.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 13 01 2020
revised: 03 03 2020
accepted: 05 03 2020
pubmed: 13 4 2020
medline: 29 8 2020
entrez: 13 4 2020
Statut: ppublish

Résumé

Modern ultrathin struts drug eluting stents (DES), due to their constructive characteristics, might be more prone to stent dislodgment than the old thick DES. Our study is aimed to retrospectively analyze and compare the incidence and outcomes of stents dislodgment in thick (TSS) and ultrathin strut stents (USS).We retrospectively analyzed the procedural and medical data of 8,564 consecutive patients (mean age 64.3 ± 11.2 years old, 4442 males) who underwent percutaneous coronary intervention with DES implantation in our Institution between 1st January 2005 to 1st January 2020. Overall, 25,692 (mean of 3.2 stent for patients) have been implanted over the study period (10648 TSS and 15044 and USS, respectively). Stent dislodgment globally occurred in 0.56% of the implanted stents (0.28% vs 0.78%, p <0.001 for TTS and USS, respectively). Coronary artery calcifications, ostial lesion, coronary artery tortuosity, and a lesion length >25 mm were independent predictors of type I and II USS dislodgments. At 12 months follow up, the rate of target lesion failure was higher in the TTS group (30.7 vs 12.7 %, p <0.001). Stent dislodgement is unusual in the modern era but is more frequent using USS than TTS DES.

Identifiants

pubmed: 32278462
pii: S0002-9149(20)30220-4
doi: 10.1016/j.amjcard.2020.03.005
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1619-1623

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Gianluca Rigatelli (G)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy. Electronic address: jackyheart@libero.it.

Marco Zuin (M)

University of Ferrara, Faculty of Medicine, Ferrara, Italy.

Dobrin Vassilev (D)

Department of Cardiology, Alexansdrovska University Hospital School of Medicine, Sofia, Bulgaria.

Fabio dell'Avvocata (F)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.

Massimo Giordan (M)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.

Luca Conte (L)

Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.

Claudio Picariello (C)

Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.

Beatrice Magro (B)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.

Paolo Cardaioli (P)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.

Loris Roncon (L)

Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH